Voyager Therapeutics Inc
Why Is Voyager Therapeutics Soaring Today?
Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX).
Analysts Remain Bullish on BioMarin Pharmaceutical
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.
Analyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.
Exploring Voyager Therapeutics’ Research Pipeline
Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications.
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.